Accumulation of $^{99m}$Tc-sestamibi in tissue is analogous to that of thallium and uptake is proportional to blood flow. In addition, tissues that are mitochondria-rich show a longer retention of $^{99m}$Tc-sestamibi (18). Sandrock et al. (11) showed that parathyroid adenomas are mitochondria-rich and that $^{99m}$Tc-sestamibi is taken up more avidly and released more slowly by these adenomas than by the surrounding thyroid (11). Early and delayed images with $^{99m}$Tc-sestamibi take advantage of its differential kinetics: $^{99m}$Tc-sestamibi, like $^{201}$TI, washes out of the thyroid gland quickly; unlike $^{201}$TI, however, it is retained in hyperfunctioning parathyroid tissue thereby allowing better visualization (19). This differential in washout times results in a 90% sensitivity for detecting parathyroid adenomas when $^{99m}$Tc-sestamibi is used as a single agent (double-phase study) (20).

Initial studies have suggested improved localization with the addition of SPECT (21–26). SPECT offers the advantages of greater tissue contrast, reasonable resolution at depth, and three-dimensional localization. Neumann et al. (27) recently reported demonstration of a mediastinal parathyroid adenoma with SPECT. The report did not indicate whether planar imaging was attempted. In comparison to $^{201}$TI, $^{99m}$Tc has higher energy that allows better penetration of the thorax. In the larger, more sensitive dose of $^{99m}$Tc-sestamibi permits shorter imaging times and facilitates the use of SPECT (28,29).

CONCLUSION

In our patient, $^{99m}$Tc-sestamibi SPECT demonstrated an abnormal focus of activity in the middle mediastinum, which correlated with a pathologically proven parathyroid adenoma that was not detected with planar imaging or prior undirected mediastinal exploration. We suggest routine use of $^{99m}$Tc-sestamibi SPECT of the mediastinum when standard planar images are negative. This case illustrates the usefulness of $^{99m}$Tc-sestamibi SPECT in localizing mediastinal parathyroid adenomas preoperatively.

REFERENCES


Somatostatin-Receptor Scintigraphy of Subcutaneous and Thyroid Metastases from Bronchial Carcinoid

Yodphat Krausz, M. Raphael Pfeffer, Benjamin Glaser and Joel Laffair

Departments of Nuclear Medicine, Oncology, Endocrinology and Pulmonary Unit, Hadassah University Hospital, Jerusalem, Israel

We present a case of bronchial carcinoid tumor with multiple metastases in the retina, subcutaneous tissues and thyroid gland. These metastatic lesions were detected by $^{111}$In-pentetreotide scintigraphy 15 yr after removal of the primary tumor. The extensive metastatic involvement documented on scintigraphy spared the patient unnecessary total thyroidectomy and directed the attention of the primary physician to previously unknown and potentially more important foci of metastatic disease.

Key Words: carcinoid; subcutaneous metastases; thyroid; retinal metastases; indium-111-pentetreotide

CASE REPORT

A 36-yr-old woman was referred to our nuclear medicine department for $^{111}$In-pentetreotide scintigraphy. Fifteen years earlier, the patient underwent a left upper lobectomy for a polypoid endobronchial carcinoid tumor, following symptoms of dyspnea and hemoptysis. The patient was completely asymptomatic for 6 yr following resection of the tumor, when she developed blurred vision in the left eye. On fundoscopy, a subretinal nodule causing mild retinal detachment in the left eye and a nodule anterior to the equator in the right eye were identified. Because of the location and size of the lesions, tissue diagnosis was not feasible without endangering the eye. The patient underwent several local treatments to the eye with laser, cryotherapy, radioactive cobalt plaque and proton beam radiotherapy with limited success.

During this time, the patient was found to have enlarged nodes in the right axilla and supraclavicular area. Biopsies demonstrated metastatic carcinoid tumor.

Fifteen years after the initial surgery, an enlarged thyroid gland was detected on physical examination. Ultrasonography disclosed multiple solid nodules in both lobes of the thyroid gland ranging in size from 3 (left) to 19 mm (right), and TeO$_4^-$ scintigraphy detected a dominant cold area in the right thyroid lobe. Fine-needle aspiration (FNA) of the palpable cold nodule disclosed multiple epithelial cells in clusters, with positive stain for chromogranin, suggestive of carcinoid tumor, and surgical removal was advised.

To determine the extent of the metastatic process prior to the suggested total thyroidectomy, $^{111}$In-pentetreotide scintigraphy was performed. Static views of the skull, neck, chest, abdomen and pelvis, together with SPECT images of the chest and abdomen, were obtained at 4 and 24 hr after tracer injection, using a single-head rotating gamma camera equipped with a medium-energy collimator.

Scintigraphy revealed multiple pathological foci in the skull, right frontal lobe of the brain, left orbit (Fig. 1), thyroid gland, mediastinum, paraaortic lymph nodes and pelvis (Fig. 2). In addition, multiple foci were also observed in the subcutaneous tissues of both arms and in the left humerus (Fig. 3). CT confirmed the findings in the skull, brain parenchyma, neck and mediastinum. It did not, however, identify the abdominal and ischial foci.

Aside from the visual defect associated with the retinal lesion, the patient has remained completely asymptomatic. Urinary 5-hydroxyindolacetic acid excretion is, however, elevated to 11.6 mg (upper limit of normal 8 mg/24 hr).

No surgical procedure was performed because of the extensive metastatic spread demonstrated scintigraphically, and the patient is now being considered for somatostatin analog therapy.
DISCUSSION

The typical carcinoid of the bronchus has a favorable prognosis (1) with a 5-yr survival of above 90% (2,3). Our patient is alive 15 yr after initial diagnosis; retinal metastases were, however, documented 6 yr after diagnosis and surgical removal of the primary tumor. Metastases to the subcutaneous tissues, bone, paraortic nodes, thyroid gland and mediastinum were detected 9 yr later.

Subcutaneous metastases of carcinoid origin have been rarely described. These lesions may be either asymptomatic (4) or tender (5). They may be the initial manifestation of a midgut tumor (4) or of a pulmonary carcinoid (5) and may precede the carcinoid syndrome by several years (4). Our patient was found to have several asymptomatic subcutaneous nodules 6 yr after the primary tumor had been removed, at the time of visual manifestations.

Recently, metastases to the thyroid gland were also observed. Metastatic involvement of the thyroid is not commonly considered in the differential diagnosis of a patient with a thyroid mass but had been reported in 4 of 70 patients (5.7%) with thyroid nodules referred for FNA in a 12-mo period (6). In that study, one patient had carcinoid tumor metastatic to the thyroid with an unlocalized primary site. Others have reported rectal (7) or small-bowel (8) carcinoid tumors metastatic to the thyroid, although these tumors usually metastasize to the regional lymph nodes or to the liver (3). Our patient has metastatic involvement of the thyroid from a primary tumor originating in the lung.

The presence of high-density somatostatin receptors on neuroendocrine tumors may suggest responsiveness to long-term octreotide therapy, as documented by Kvols et al. (9). In carcinoid patients, somatostatin analog therapy has been associated with excellent symptomatic relief and improved survival, despite the paucity of convincing evidence for in vivo tumor regression. Continued treatment of somatostatin-receptor positive patients with somatostatin analogs may be advantageous, even in the absence of hormone-related symptoms, as is the case for this patient.

Surgical resection of isolated metastatic foci may have been indicated in this patient, given the poor response of carcinoid tumors to chemotherapy. In fact, thyroidecmy was recommended despite the presence of metastases in the eye, since these were partially controlled by local treatment. However, the extensive metastatic disease documented on 111In-pentetreotide scintigraphy spared the patient unnecessary thyroid surgery. Furthermore, it directed the primary physician to a previously unsuspected lesion in the brain parenchyma.

REFERENCES